A multibillion-dollar deal gives Gilead subsidiary Kite Pharma exclusive rights to Sangamo Therapeutics’ zinc finger nuclease (ZFN) gene-editing approach to create next-generation, off-the-shelf and personalized CAR T-cell therapies.
Sangamo will receive $150 million upfront and is eligible for more than $3 billion in future payments tied to regulatory and other milestones.
“We believe Sangamo’s zinc finger nucleases provide the optimal gene editing platform,” said Gilead CEO John Milligan, PhD, in a statement. “We look forward to working with Sangamo to accelerate our efforts to develop next-generation autologous cell therapies, as well as allogeneic treatments that can be accessed more conveniently in the hospital setting for people living with cancer.”
Sources: Endpoints News, February 22, 2018; Reuters, February 22, 2018.